Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

53 results about "Splicing factor" patented technology

A splicing factor is a protein involved in the removal of introns from strings of messenger RNA, so that the exons can bind together; the process takes place in particles known as spliceosomes. Genes are progressively switched off as we age, and splicing factors can reverse this trend.

Method and apparatus for speculating variable splicing function based on single cell transcriptome data

The present application relates to the field of bioinformatics. In particular, the present application relates to methods and apparatus for speculating variable splicing functionality based on single cell transcriptome data. The method comprises the following steps: determining a variable splicing mode of each gene in a data set in a cell; determining the incidence relation between the variable splicing mode and the gene expression of each gene; a variable splicing mode module is determined according to the incidence relation between the variable splicing modes and the gene expression, and the variable splicing mode module is a variable splicing mode set obtained through clustering according to the correlation between the variable splicing modes and the cell phenotypes; displaying the cell splicing heterogeneity according to the variable splicing mode module; and / or determining a potential regulatory mechanism between the variable splicing mode and the gene expression according to the variable splicing mode module, the potential regulatory mechanism being used for embodying key splicing factors in the gene expression, and a biological approach in which the variable splicing mode affects the cell phenotype.
Owner:SHENZHEN HUADA GENE INST

Targeting gpatch8 for treating SF3b1-mutant cancers

PCT designated stage expiredWO2024234005A2VectorsAntibody mimetics/scaffoldsOncologyMutant
Embodiments of the present disclosure provide methods for treating a subject with cancer, wherein the cancer is characterized by a change-of-function or loss of-function mutation in a recurrently mutated RNA splicing factor gene. In some embodiments, the method can comprise administering to a subject a therapeutically effective amount of a composition that inhibits expression of a trans-acting splicing factor and / or inhibits expression of a cis-acting splicing factor, wherein a cancer-causing error triggered by the change-of-function or loss-of-function mutation in a recurrently mutated RNA splicing factor gene is partially or fully rescued by inhibiting expression of the trans-acting splicing factor and / or inhibiting expression of the cis-acting splicing factor.
Owner:FRED HUTCHINSON CANCER CENT +1

Corn drought-resistant gene ZmMBF1 and application thereof

The invention discloses a corn drought-resistant gene ZmMBF1 and application thereof. The nucleotide sequence of CDS of the drought-resistant gene ZmMBF1 is as shown in SEQ ID NO: 1. The amino acid sequence of the drought-resistant protein ZmMBF1-P002 coded by the gene is as shown in SEQ ID NO: 2. The target gene ZmMBF1 is obtained based on co-expression network analysis of splicing factor expression quantity and transcript expression proportion of differential splicing genes, the gene encodes an MBF1 family protein, and the drought resistance of corn can be improved after the gene is over-expressed.
Owner:HUAZHONG AGRI UNIV

Modulators of the mitotic cell cycle in cancer cells and uses thereof for the treatment of cancer

The present invention relates to a method for identifying a compound that modulates the mitotic cell cycle in cancer cells by modulating at least one of the expression, the amount, the stability and / or the biological activity of the protein CITED2 and / or CITED2 containing protein complexes in a mammalian cell. Further provided is a method for determining the level of CITED2 and / or CDK11bp58 and / or splicing factor 3B subunit 1 (SF3B1), and / or 14-3-3γ in a sample obtained from a subject, comprising detecting of binding of CITED2 in the sample to at least one molecule selected from the group consisting of CDK11bp58, splicing factor 3B subunit 1 (SF3B1), and 14-3-3γ, wherein a decrease of the binding, when compared to a control indicates an improper centrosome segregation and subsequent an increase of the formation of chaotic monopolar mitotic spindles in said sample. Further provided are pharmaceutical compositions comprising the compound as identified for use in medicine, in particular for use in the prevention or treatment of a disease or condition caused by cancer.
Owner:CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG SPEYER HAUS +1

Splicing factor WBP11, application of inhibitor of splicing factor WBP11 and medicine for preventing or treating colorectal cancer

The invention belongs to the technical field of antitumor drug research, and particularly relates to a splicing factor WBP11, application of an inhibitor of the splicing factor WBP11 and a drug for preventing or treating colorectal cancer. Researches show that knockdown of the WBP11 significantly inhibits proliferation and invasion migration of colorectal cancer cells, the expression quantity of the WBP11 in colorectal cancer tissues is higher than that of the WBP11 in corresponding normal tissues, and the high expression of the WBP11 causes poor prognosis of the colorectal cancer. Furthermore, the invention also designs siRNA and Cas knock-down plasmids aiming at WBP11, and the siRNA and Cas knock-down plasmids are proved to have good tumor development inhibition effects and are expected to be applied to development of anti-colorectal cancer drugs.
Owner:SOUTHWEST MEDICAL UNIV

Application of SF3A2 in triple-negative breast cancer treatment and chemotherapy efficacy evaluation

The application provides application of a selective splicing factor SF3A2 as a biomarker in preparation of a reagent for breast cancer diagnosis, treatment, prognosis evaluation and chemotherapy sensitivity evaluation. The application provides application of a detection reagent for expression level of a selective splicing factor SF3A2 gene or protein in preparation of a kit for breast cancer diagnosis, prognosis evaluation and chemotherapy sensitivity evaluation. Further, the application provides application of an expression inhibitor for a selective splicing factor SF3A2 gene or protein in preparation of a kit for breast cancer treatment and chemotherapy sensitivity improvement.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Cell-protective compounds and their uses

The present invention relates to cytoprotective compounds and their uses. The present invention relates to cytoprotective, particularly cardioprotective and renoprotective organic compounds, preferably organic compounds that inhibit substrate phosphorylation caused by G protein-coupled receptor kinase 2 (GRK2, ADRBK1). Preferably, the organic compounds inhibit GRK2-mediated phosphorylation of serine / arginine-rich splicing factor 1 (SRSF1, ASF-1, SF2) and / or photosensory factors for the treatment of hypertension, heart disease, cardiac dysfunction or failure, and heart disease-related conditions such as cardiomyocyte necrosis, ischemic heart disease and / or ischemic heart injury or aging. In addition, the present invention relates to methods for identifying inhibitors of (GRK2)-mediated (SRSF1) and / or photosensory factor phosphorylation.
Owner:ETH ZURICH

Application of novel SRSF1 splicing factor small molecule inhibitor okanin and pharmaceutical composition thereof

The application discloses application of a novel SRSF1 splicing factor small molecule inhibitor Okanin and a medicine composition thereof, wherein the medicine composition comprises an active ingredient, and the active ingredient comprises the SRSF1 splicing factor small molecule inhibitor Okanin and an immune checkpoint inhibitor alpha PD-1; the direct action target of Okanin is an RNA binding core region of SRSF1 protein, the downstream glycolysis function of SRSF1 is prevented from being exerted, and thus tumor cell proliferation is inhibited. Meanwhile, Okanin can act on CD8+ T cells, the effector function of the CD8+ T cells is enhanced, and thus the activity of the CD8+ T cells in killing tumor cells is improved.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV

Methods for detecting multiple sclerosis (MS) diagnostic autoantibodies

Methods for detecting Multiple Sclerosis (MS) diagnostic autoantibodies in a subject and generating a subject-specific, MS diagnostic autoantibody profile are described. The methods include contacting an immunoglobulin-containing biological sample from the subject with a system comprising antigens that form immunocomplexes with MS diagnostic autoantibodies, the antigens including general transcription factor II-I, splicing factor 1, and inducible T-cell co-stimulator (ICOS), to form a reaction mixture, under conditions that allow for formation in the reaction mixture of an immunocomplex between each antigen and its corresponding MS diagnostic autoantibody, if its corresponding MS diagnostic autoantibody is present in the sample; and detecting presence or absence of immunocomplexes in the reaction mixture, wherein formation of immunocomplexes between the antigens and their corresponding MS diagnostic autoantibodies indicates presence of the MS diagnostic autoantibodies in the biological sample.
Owner:ROWAN UNIVERSITY

Use of splicing factor WBP11 and its inhibitor, and medicine for preventing or treating colorectal cancer

The present invention belongs to the technical field of anti-tumor drug research, and specifically relates to a splicing factor WBP11 and uses of its inhibitors, and drugs for preventing or treating colorectal cancer. WBP11 Significantly inhibited the proliferation, invasion and migration of colorectal cancer cells, and WBP11 The expression level in colorectal cancer tissues is higher than that in corresponding normal tissues. WBP11 High expression of TNF-α leads to poor prognosis of colorectal cancer. WBP11 It has been confirmed that both siRNA and Cas knockdown plasmids have good effects in inhibiting tumor development and are expected to be used in the development of anti-colorectal cancer drugs.
Owner:SOUTHWEST MEDICAL UNIV

Splicing factor gene mutation-associated neoantigenic peptides and uses thereof

PendingCA3318528A1Genes mutationAntigen
The present disclosure relates to methods and compositions that involve isolated peptides derived from SF3B1 mutation-associated tumors, and the use of such methods and compositions for treatment or prevention of cancer.
Owner:REGENERON PHARMACEUTICALS INC

Generation of mature neurons differentiated from pluripotent stem cells

Methods for generating mature neurons differentiated from pluripotent stem cells, such as to facilitate the study of late-onset neurodegenerative disease, are disclosed. The methods include overexpressing the splicing factor muscleblind like splicing regulator 2 (Mbnl2) in cortical neurons. In some aspects, the method further comprises overexpressing RNA binding fox-1 homolog 1 (Rbfox1) and / or reducing expression of polypyrimidine tract binding proteins PTBP1 / 2. The methods also include accelerated derivation of mature neuron and generation of a tau pathology model. Also disclosed are constructs and compositions for accelerated derivation of mature neuron and / or generation of a tau pathology model.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Precursor mRNA Splicing Factor Gene RDM16 of Arabidopsis thaliana and Its Application in Plant High Temperature Regulation

ActiveCN118345088BPlant peptidesFermentationBiotechnologyRNA Precursors
The present invention discloses an Arabidopsis thaliana precursor mRNA splicing factor gene RDM16 and its application in plant high temperature regulation, relating to the field of genetic engineering technology. The nucleotide sequence of the Arabidopsis thaliana mRNA splicing factor gene RDM16 is shown in SEQ ID NO.1. The present invention uses wild-type Arabidopsis thaliana Col-0 and its mutant rd-4 and transgenic plants complemented with the RDM16 gene (RDpro:RDM16-GFP / rd-4#3, 12) to identify that the functional loss of the Arabidopsis thaliana RDM16 gene reduces the high temperature tolerance of Arabidopsis thaliana, that the expression of the RDM16 gene improves the high temperature tolerance of Arabidopsis thaliana, and that the RDM16 gene is located in the cell nucleus. It is also verified that the RDM16 protein can interact with the high temperature response protein STA1 to form a protein complex, thereby improving the high temperature tolerance of Arabidopsis thaliana by promoting the splicing of the heat shock transcription factor HSFA3.
Owner:ANHUI AGRICULTURAL UNIVERSITY

Targeting gpatch8 for treating sf3b1-mutant cancers

Embodiments of the present disclosure provide methods for treating a subject with cancer, wherein the cancer is characterized by a change-of-function or loss of-function mutation in a recurrently mutated RNA splicing factor gene. In some embodiments, the method can comprise administering to a subject a therapeutically effective amount of a composition that inhibits expression of a trans-acting splicing factor and / or inhibits expression of a cis-acting splicing factor, wherein a cancer-causing error triggered by the change-of-function or loss-of-function mutation in a recurrently mutated RNA splicing factor gene is partially or fully rescued by inhibiting expression of the trans-acting splicing factor and / or inhibiting expression of the cis-acting splicing factor.
Owner:FRED HUTCHINSON CANCER CENT +1

Kit for detecting anti-serine / arginine-rich splicing factor 9-IgG antibodies

ActiveCN114895024BDisease diagnosisBiological testingSerine-Arginine Splicing FactorsArginine
The present invention provides a kit for detecting anti-serine / arginine-rich splicing factor 9-IgG antibodies, which consists of an antigen protein rich in serine / arginine splicing factor 9, a solid phase carrier, a labeled antibody, an antigen diluent, a sample dilution buffer, an antibody diluent, a substrate color developer, a washing solution, a standard substance, a positive quality control product, and a negative quality control product. Anti-serine / arginine-rich splicing factor 9-IgG autoantibodies are detected by a specific kit. The present invention identifies autoantibodies against the target antigen rich in serine / arginine splicing factor 9 for the first time, and provides a detection kit for the autoantibodies. The kit provided by the present invention provides a basis for the molecular mechanism research and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to serine / arginine-rich splicing factor 9 and serine / arginine-rich splicing factor 9-IgG autoantibodies at home and abroad.
Owner:ZHEJIANG UNIV

Antisense oligonucleotide medicine for treating pituitary tumor

The invention discloses an antisense oligonucleotide medicine for treating pituitary tumor. According to evidence of molecular biology experiments and the like and verification in human primary pituitary tumor cells, the designed specific ASO medicine is applied to treatment of pituitary tumors for the first time. The ASO drug inhibits the expression of MDM2, recovers the activity of P53 protein, inhibits the proliferation of pituitary tumors and promotes apoptosis by inhibiting the splicing process mediated by a splicing factor FUS, and provides a new direction for a potential medication scheme for pituitary tumor treatment.
Owner:BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

T cell receptors targeting mutations in RNA splicing factors

This document provides isolated immune cells that include an exogenous T cell receptor (TCR) having affinity for a splicing factor 3B subunit 1A (SF3B1) peptide as well as methods and materials for making such immune cells. For example, isolated immune cells that included an exogenous TCR having affinity for a mutant SF3B1 peptide, methods and materials for making such immune cells, and methods and materials for using such immune cells to treat mammals (e.g., a human having cancer) are provided.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

SRPK1 inhibitors and methods of use

Provided herein are compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are useful as modulators of serine / arginine rich splicing factor protein kinase-1 (SRPK1). Further disclosed herein are methods for treating cancer and vascular diseases and disorders.
Owner:ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO LTD +1

Pathogenic gene prediction method based on whole transcriptome correlation research and related equipment

The application relates to the technical field of pathogenic gene prediction, and provides a pathogenic gene prediction method based on whole-transcriptome correlation research and related equipment. The method provided by the application comprises the following steps: calculating a splicing percentage matrix of each gene according to an RNA-seq sample; obtaining a genotype matrix of each gene and a genotype matrix of each splicing factor; constructing a first prediction model based on the genotype matrix of all splicing factors and all splicing percentage matrices, and obtaining a predicted splicing percentage matrix corresponding to all splicing factors by using the first prediction model; constructing a second prediction model based on the predicted splicing percentage matrix and the genotype matrix of all genes, and obtaining a final predicted splicing percentage matrix of all genes by using the second prediction model; and performing pathogenicity analysis according to the final predicted splicing percentage matrix of all genes to obtain a gene pathogenicity prediction result. The method provided by the application can improve the accuracy of pathogenic gene prediction.
Owner:CENT SOUTH UNIV

Use of hnRNPL in preparation of glioma diagnosis, treatment and prognosis evaluation products

The application discloses application of hnRNPL in preparation of glioma diagnosis, treatment and prognosis evaluation products, and belongs to the technical field of biological medicine. Through bioinformatics and clinical sample verification, it is confirmed that hnRNPL is significantly highly expressed in glioma tissues, and the expression level thereof is negatively correlated with the total survival period of patients, and hnRNPL has the function of promoting the occurrence and development of glioma. Mechanism research shows that hnRNPL can be used as a key alternative splicing factor, which promotes the skipping of the second exon of SH3BGRL by combining with the CA-rich sequence on the SH3BGRL pre-mRNA, thereby generating functional SH3BGRL protein, and driving the proliferation, migration and invasion of glioma cells. Based on this, hnRNPL can be used as a molecular marker for the diagnosis and prognosis evaluation of glioma, and an inhibitor targeting hnRNPL can effectively inhibit the malignant progression of glioma.
Owner:TIANJIN MEDICAL UNIVERSITY GENERAL HOSPITAL

Improvement of Tumor Immunogenicity by Means of Splicing-Controlling Compound

Provided is a pharmaceutical composition that can improve tumor immunogenicity. The present disclosure relates to a pharmaceutical composition containing, as an active ingredient, a splicing controlling compound that modulates the activity of serine / arginine-rich splicing factors (SRSFs).
Owner:KYOTO UNIV

Pathogenic gene prediction method based on whole transcriptome association research and related equipment

The invention relates to the technical field of virulence gene prediction, and provides a virulence gene prediction method based on whole transcriptome association research and related equipment. The method comprises the following steps: calculating a splicing percentage matrix of each gene according to an RNA-seq sample; obtaining a genotype matrix of each gene, and obtaining a genotype matrix of each splicing factor; constructing a first prediction model based on the genotype matrix of all the splicing factors and all the splicing percentage matrixes, and obtaining predicted splicing percentage matrixes corresponding to all the splicing factors by using the first prediction model; constructing a second prediction model based on the predicted splicing percentage matrix and the genotype matrix of all the genes, and obtaining a final predicted splicing percentage matrix of all the genes by using the second prediction model; and carrying out pathogenicity analysis according to the final prediction splicing percentage matrix of all the genes to obtain a gene pathogenicity prediction result. The method provided by the invention can improve the accuracy of virulence gene prediction.
Owner:CENT SOUTH UNIV

Cancer therapy of subjects carrying mutations in a splicing factor gene

The present invention is directed to SEL24 / MEN1703 for use in the treatment of a patient suffering from cancer and / or for use in increasing the overall survival of a patient suffering from cancer, wherein the cancer is myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), and wherein said patient carries at least one mutation in at least one gene associated with splicing.
Owner:BERLIN CHEMIE AG +1

Compositions comprising intermediate non-coding RNA modulators that modulate expression of ETV6 or FOXO1 and uses thereof

The present invention relates to: a composition for modulating the expression of FOXO1 and / or ETV6, the composition comprising one or more intermediate non-coding RNA modulators; a composition for attenuating splicing factor expression, the composition comprising an expression modulator of FOXO1 and / or ETV6; a composition for attenuating cell senescence and / or reentry into the cell cycle, the composition comprising FOXO1 and / or ETV6 or an expression modulator of a downstream target thereof involving splicing factor expression; or a composition capable of modulating splicing factor expression, the composition comprising one or more compounds capable of binding or inhibiting the FOXO1 and / or ETV6 gene or a downstream target thereof involving splicing factor expression. Such compositions have therapeutic benefits in preventing, managing, ameliorating or treating aging-related diseases or conditions or cancers, and also as research tools / agents.
Owner:SENISCA LTD